title: Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women.
abstract: Premenopausal women meeting operational criteria for idiopathic, acquired, global hypoactive sexual desire disorder were studied in a randomized, double-blind, placebo-controlled, multiple-site escalating dose 112-day trial of bupropion sustained release. Outcome was measured by investigator-rating and self-administered questionnaires. All measures indicated greater sexual responsiveness in women receiving bupropion. The Changes in Sexual Functioning Questionnaire indicated that bupropion had significant effects on increasing measures of sexual arousal, orgasm completion, and sexual satisfaction.
authors.affiliation: Department of Psychiatry, Case Western Reserve University and Metro-Health Medical System, 2500 MetroHealth Drive, Cleveland, OH 44109-1998, USA. Rsegraves@metrohealth.org
authors.forename: Robert Taylor
authors.initials: RT
authors.lastname: Segraves
authors.forename: Anita
authors.initials: A
authors.lastname: Clayton
authors.forename: Harry
authors.initials: H
authors.lastname: Croft
authors.forename: Abraham
authors.initials: A
authors.lastname: Wolf
authors.forename: Jill
authors.initials: J
authors.lastname: Warnock
mesh_terms: D000328:Adult; D016642:Bupropion / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017697:Premenopause / Q000187:drug effects* / Q000502:physiology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
chemical_list: D003692:Delayed-Action Preparations; D016642:Bupropion